EDGAR Filing Documents for 0001140361-18-013588

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:

SEC Accession No. 0001140361-18-013588

Filing Date

2018-03-15

Accepted

2018-03-15 14:54:04

Documents

Effectiveness Date

2018-03-15

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	s002111x2_8k.htm	DEFA14A	50851
2	EXHIBIT 4.1	s002111x2_ex4-1.htm	EX-4.1	191965
3	EXHIBIT 10.1	s002111x2_ex10-1.htm	EX-10.1	992934
4	EXHIBIT 10.2	s002111x2_ex10-2.htm	EX-10.2	136767
5	EXHIBIT 10.3	s002111x2_ex10-3.htm	EX-10.3	202001
6	EXHIBIT 10.4	s002111x2_ex10-4.htm	EX-10.4	79945
7	EXHIBIT 99.1	s002111x2_ex99-1.htm	EX-99.1	30527
8	EXHIBIT 99.2	s002111x2_ex99-2.htm	EX-99.2	154359
9	EXHIBIT 99.3	s002111x2_ex99-3.htm	EX-99.3	4971
10		s002111_ex991-image1.jpg	GRAPHIC	9242
11		s002111_ex991-image2.jpg	GRAPHIC	92305
	Complete submission text file	0001140361-18-013588.txt		1985384

Mailing Address 2855 GAZELLE CT CARLSBAD CA 92010

Business Address 55 CAMBRIDGE PARKWAY SUITE 100 CAMBRIDGE MA 02142 760-603-2732

AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)